NCT02632344View on ClinicalTrials.gov

Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

February 28, 2022

Study Completion Date

December 31, 2025

Conditions
Recurrent Respiratory Papillomatosis
Interventions
DRUG

Pembrolizumab

200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.

Trial Locations (2)

60208

NorthShore University HealthSystem, Evanston

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER